RankAlpha logo
Back to Rankings

JSPR

Jasper TherapeuticsA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
Briquilimab still has a differentiated CSU signal, and management said the updated BEACON/OLE dataset was sufficient to select two active doses and refile the Phase 2b protocol, keeping the program alive for a 2H26 start if funding is secured [#SEC-8K-2026-03-30] [#SEC-8K-2026-05-14].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
Additional funding is required before the planned Phase 2b CSU study can begin, creating a near-term financing and dilution overhang [#SEC-8K-2026-05-14].
Momentum
61
Value
58
Sentiment
68
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.62 · Bull $1.25 · Bear $0.14
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-02 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $11.80
Why
Momentum61 · Δ7d -
Value58 · Δ7d +0.0
Sentiment68 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
61
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
58
32% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.0
Sentiment
68
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade A. Momentum 61.3 / Value 58.2 / Sentiment 68.4

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$14.96M
Beta
3.09
Shares Out
27.98M
P/E (TTM) · Derived
-0.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.11
Rev YoY
-
EPS YoY
+9.4%
Gross Margin
-
Op Margin
-
Net Debt
-$71.64M
Current Ratio
2.59
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology